Study to Evaluate the Safety and Immunogenicity of VPM1002 in Comparison With BCG in HIV-exposed/-Unexposed Newborn Infants in South Africa

NCT02391415 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

416

Enrollment

INDUSTRY

Sponsor class

Conditions

Tuberculosis

Interventions

BIOLOGICAL: VPM1002
BIOLOGICAL: BCG
BIOLOGICAL: VPM1002(Hyg+)

Sponsor

Serum Institute of India Pvt. Ltd.

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]